CJC-1295 and Ipamorelin: Combination Claims and Study Evidence
Published
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
CJC-1295 and ipamorelin are often discussed together because both can stimulate growth-hormone signaling through different receptors. That biological rationale does not establish that their combination improves recovery, sleep, strength or longevity. The most useful comparison starts with the exact molecules, then asks whether a study tested one compound or both—and what it actually measured.
Direct answer: Separate human studies document hormonal responses to CJC-1295 and ipamorelin. Our focused November 11, 2026 literature and trial-registry search did not identify a controlled human trial of the exact CJC-1295–ipamorelin combination. Evidence from individual agents cannot establish a blend's effectiveness or safety.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs. This commercially interested, AI-assisted summary is not an independent scientific review. It evaluates research evidence and does not provide a treatment or administration protocol.

What are CJC-1295 and ipamorelin?
CJC-1295 belongs to the growth-hormone-releasing hormone, or GHRH, family. Ipamorelin is a growth-hormone secretagogue acting through the ghrelin receptor. They therefore represent different ways of stimulating a hormonal pathway; they are not interchangeable ingredients. FDA's scientific evaluations describe these identities and their distinct pharmacology. FDA CJC-1295 evaluation, FDA ipamorelin evaluation
Comparison | CJC-1295 research | Ipamorelin research |
|---|---|---|
Relevant signaling route | GHRH receptor | Ghrelin receptor |
Essential identity question | Does the material include the DAC modification? | Which molecular form and formulation were studied? |
Early human endpoints | Growth hormone, IGF-I and persistence in the body | Drug concentrations and growth-hormone response |
Evidence-transfer problem | Long-acting DAC findings do not establish No-DAC effects | Single-agent findings do not establish combination effects |
The phrase “CJC-1295 without DAC” requires particular care. FDA distinguishes CJC-1295 and CJC-1295 DAC as different active moieties and says they are not interchangeable. The DAC modification allows albumin binding, which changes persistence in circulation. A catalog name alone does not authenticate sequence, modification or identity. FDA identity analysis
The widely cited long-acting CJC-1295 human research concerns the albumin-binding compound. Removing DAC is not a minor labeling change that preserves all findings. Our CJC-1295 DAC identity guide examines this naming problem in more detail.
What did the human studies actually test?
Original study | Design and population | Main finding or measurement | Combination evidence? |
|---|---|---|---|
Teichman, 2006 | Two randomized, blinded, placebo-controlled studies lasting 28 and 49 days in healthy adults | Sustained growth-hormone and IGF-I increases | No; CJC-1295 alone |
Gobburu, 1999 | Healthy male volunteers; pharmacokinetic and pharmacodynamic investigation | Concentration-related growth-hormone response | No; ipamorelin alone |
Beck, 2014 | Randomized, blinded, placebo-controlled phase 2 study after bowel resection | No statistically significant improvement in the key time-to-meal endpoint | No; ipamorelin alone |
The Teichman study establishes a measurable endocrine effect under its study conditions. It does not establish improved sleep, exercise recovery or long-term health. A related CJC-1295 study of growth-hormone pulsatility also measured hormonal patterns, rather than those clinical benefits.
The Gobburu ipamorelin study modeled the relationship between exposure and growth-hormone release. It did not measure improved body composition or physical functioning.
The postoperative trial by Beck and colleagues enrolled 117 adults and included 114 in its safety and modified intention-to-treat populations. The main efficacy difference was not statistically significant. This is useful negative evidence for that particular bowel-recovery question, not proof that ipamorelin has no biological activity. The publisher reports Helsinn Therapeutics funding; only the abstract and accessible article information were reviewed here.
Why two mechanisms do not prove a combination works
A combination study must test the combination. Comparing it with each ingredient and an appropriate control can show whether adding the second agent improves the outcome, adds risk, or changes nothing important. Separate studies cannot answer that question because participants, molecular forms, exposures and endpoints differ.
Likewise, a larger hormone response would not automatically establish a better clinical result. Growth hormone and IGF-I are biological measurements. Claims about strength require strength testing; claims about sleep require defined sleep outcomes; longevity claims require evidence relevant to survival and health over time.
Our focused PubMed search returned reviews and an analytical detection study, rather than a controlled human combination trial. The matching ClinicalTrials.gov search returned no records. This is a bounded search result, not proof that every unpublished, unregistered or differently indexed study has been excluded.
The ipamorelin endpoint guide explains why identifying the measured outcome is central to interpreting a peptide paper.
What remains uncertain about safety?
Short studies cannot reliably measure uncommon or delayed harms. “No serious adverse reactions” in a small early study is therefore a description of that study, not a general safety guarantee.
FDA's current compounding-safety page identifies CJC-1295 concerns involving immune reactions, peptide impurities and serious reactions including increased heart rate and systemic vasodilation. It also describes ipamorelin-related safety uncertainty and serious events in an intravenous postoperative study. FDA safety information
FDA's detailed ipamorelin review notes two deaths after postoperative complications and says their relationship to ipamorelin was unclear. Reporting those events does not establish causation; omitting the uncertainty in either direction would misrepresent the evidence. FDA ipamorelin safety review
An untested combination introduces an additional question: whether its risks differ from those of either ingredient. Neither a purity percentage nor a shared mechanism resolves that uncertainty. The growth-hormone research hub and guide to reading a peptide study provide related evidence-reading resources.
Review method and source access
Reviewed November 11, 2026. Sources include original PubMed abstracts, the publisher's postoperative-trial abstract, full FDA scientific evaluations and the current FDA safety page. The focused searches used CJC-1295/CJC1295 with ipamorelin in PubMed and both compound names in ClinicalTrials.gov. Full journal texts were not available for all studies. FDA advisory briefing materials are scientific evaluations, not final approval decisions; no independent clinical review is claimed.
Catalog materials are for lawful laboratory research only, not human or veterinary use. Published studies do not verify a supplied lot.
